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With our current view of alopecia areata as an autoim-
mune disease, it is probable that disease development
in an individual is dependent on multiple genetic and
environmental factors interacting in a complex system.
Rodent models a¡ord the opportunity to investigate
alopecia areata development and to de¢ne the signi¢-
cance of the di¡erent factors involved. Recently, rodent
model characterization has been conducted using £ow
cytometry, microarray analysis, and functional studies.
From these a pattern of events in alopecia areata devel-
opment has emerged. Although the preliminary activa-
tion events for the onset of alopecia areata remain
unknown, the response of the immune system is char-
acterized by antigen presentation and costimulation of
lymphocytes in the lymph nodes and skin, a de¢ciency
of CD4þ/CD25þ regulatory cells, and an action of
activated lymphocytes on hair follicles via Fas/FasL sig-
naling and cytokines. Thus, onset of disease may re-
quire appropriate (or inappropriate) expression of
stimulatory antigens within the hair follicle, the break-
down of the putative hair follicle immune privilege, the
presentation of antigens to the immune system, a failure
of immune system regulation, and the ability of the
activated immune system to disrupt anagen-stage hair
follicles. Once the sequence of events is initiated, it
may become a self-perpetuating cycle, with epitope
spreading leading to a wider range of targets in chronic
alopecia areata. Rodent model studies have provided
signi¢cant insight into alopecia areata, but much more
remains to be explained about the mechanisms of
disease development. Keywords: in£ammation/autoim-
mune disease/mouse model. JID Symposium Proceedings
8:182 ^187, 2003
H
uman alopecia areata (AA) is clinically, pathologi-
cally, and genetically a heterogeneous disease de-
¢ned by a number of criteria (Ho¡mann and
Happle, 1999). It most likely comprises several dis-
ease subsets that may be caused by multiple patho-
genic mechanisms. There are now several candidate AA models
available, including SCID/human xenograft, spontaneous disease
development in a variety of domesticated species, and sponta-
neous and induced disease in inbred rodent strains (Gilhar et al,
1998; McElwee et al, 1998a; McElwee et al, 1998b; McElwee et al,
1999a; Smyth and McNeil, 1999). Each of these models has the
potential to provide signi¢cant insight into the mechanisms of
human AA. As with research on other autoimmune diseases
(Gri⁄ths and Remmers, 2001), each model may not re£ect the
full range of highly variable clinical and pathological presenta-
tions observed in humans; however, collectively they may de¢ne
common, fundamental parameters and individually yield infor-
mation on particular subforms of the disease. The most exten-
sively characterized model to date is the C3H/HeJ mouse
(Sundberg et al, 1994). This model meets the basic criteria of AA:
The disease is tissue speci¢c, a¡ecting anagen-stage hair follicles;
hair follicle morphology is disrupted, but no scar tissue is formed
in response to the in£ammatory in¢ltrate; no persisting infectious
agents have been found that could explain in£ammation; and the
disease is chronic but potentially reversible with immunomodu-
latory treatments or by spontaneous remission. Most recently, this
model was extensively examined using £ow cytometry and mi-
croarray analysis and subsequent functional studies. From these
studies an understanding of mouse AA development has emerged
(McElwee and Ho¡mann, 2002).
Currently, AA is generally regarded as an autoimmune disease,
although the antigenic target(s) of attack has not yet been proved
(McElwee et al, 1999b). Classically, autoimmune diseases are con-
trolled through a complex interaction between multiple genetic
and epigenetic factors. The activity of these components working
synergistically and antagonistically likely determines the degree
of disease susceptibility, actual disease onset, severity, duration,
and potential spontaneous or treatment-induced resolution of
the condition. Genes and environmental modulation of autoim-
munity can operate within the individual at three primary levels:
the overall reactivity of the immune system, the speci¢c antigen
and its presentation, and the target tissue itself (Marrack et al,
2001). For an understanding of AA as an autoimmune disease,
each of these areas requires investigation.
IMMUNE SYSTEM REACTIVITY
Environmental stressors The events that lead to autoimmune
disease in humans remain unresolved. It has been postulated
that antigenic determinants of pathogens that cross-react with
target organ^expressed antigens may trigger an autoimmune res-
ponse by molecular mimicry and that this ultimately leads to
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autoimmune disease (Oldstone, 1998; Hiemstra et al, 2001).
Alternatively, an infectious agent could induce cellular injury
and release self antigens, generating cytokine-mediated by-
stander activation of self-reactive lymphocytes that cross-react
with additional, but genetically distinct, self antigens (Horwitz
et al, 1998; Regner and Lambert, 2001). Similar events have been
postulated and discounted for AA over many years, and research
on C3H/HeJ mice has failed to de¢ne a candidate infectious agent
(Sabouraud, 1896; Ikeda, 1967; Skinner et al, 1995; Jackow et al,
1998; McElwee et al, 1998c). It is possible, however, that the
inciting agent is only transiently expressed and that analysis of
individuals or models downstream of the activating event yields
a negative result. The viral or microbial infection that initiates
the autoimmune phenomenon may not be present by the time
overt disease develops (Oldstone, 1998). Thus, the possibility of
exogenous agent involvement in AA onset cannot be ruled out.
It is also possible that the general viral and vaccine load on the
immune system may raise sensitivity and reactivity and increase
the probability of an inappropriate immune response in an
immune system with genetically determined instability.
Other exogenous immune system stimuli may be involved in
AA susceptibility. In the mouse model, diet, speci¢cally soy oil
content, has been identi¢ed as one factor capable of increasing
resistance to AA development. Mice fed a diet high in soy oil
were less likely to develop AA after skin grafting, a known
method of transferring AA between a¡ected and una¡ected
animals (McElwee et al, 1998b). In part, this resistance may be
due to soy iso£avones such as genistein. The challenge from the
skin graft and the subsequent failure of overt AA development
lead to an alteration in the immune system with a possible
increase in activation-induced cell death in the spleen (McElwee
et al, 2002). Gonadal hormones have been identi¢ed as a fur-
ther AA susceptibility^modifying factor in the mouse model.
While estrogen supplementation may increase disease severity,
testosterone supplementation can inhibit disease onset in the
skin graft^induced model (McElwee et al, 2001). These and other
studies demonstrate that, while AA susceptibility in rodent
models and humans is genetically determined, signi¢cant input
from the environment may modulate disease onset, severity,
persistence, and remission, in part because of modulating general
immune system reactivity.
AA frequency and severity are apparently associated with a
greater frequency of allergies as compared to the general
population (Muller and Winkelmann, 1963; Ikeda, 1965; Penders,
1968; De Waard-van der Spek et al, 1989; Weise et al, 1996). It
remains to be seen whether there is a direct relationship whereby
an allergic response is capable of increasing immune system
sensitivity and instability such that AA susceptibility increases,
or whether the increased frequency of allergies in AA patients is
merely a re£ection of genetically determined immune system
sensitivity. In rodent models, the incidence of allergies has not
been investigated, although the DEBR model has a high degree
of sensitivity to anesthesia (McElwee, in press). Stress has been
suggested as a potential instigator of autoimmune diseases,
possibly through glucocorticoid modulation of in£ammatory
cytokine expression (Elenkov and Chrousos, 2002). Stress has
also been postulated as a potential in£uence on AA develop-
ment, but, although the circumstantial evidence is signi¢cant,
little direct evidence is available in support of the claim
(Mehlman and Griesemer, 1968; Colon et al, 1991; Liakopoulou
et al, 1997; Kavak et al, 2002). Other promoters of the immune
system in autoimmune diseases may include drugs and toxins
(Bigazzi, 1994; Elkayam et al, 1999; Holsapple, 2002; Lawrence
and McCabe, 2002). In principle, one or more of these factors
may modulate the immune system in AA, but in practice little
is known about the e¡ects of environmental stimuli on rodent
models or humans.
Autoreactive leukocytes For hair follicles to be targeted and
overt hair loss to occur, relevant autoreactive cell subsets must be
present in an activated state and in signi¢cant numbers such that
the follicles are adversely a¡ected. The primary cell types found
around and within human and rodent AA-a¡ected hair follicles are
CD4þ and CD8þ (Ranki et al, 1984; Zhang and Oliver, 1994).
Recent £ow cytometry studies de¢ned a signi¢cant
skin in¢ltrate of these cells, whereas skin-draining lymph
nodes contain an increased percentage and total number of
antigen-presenting cells (Z˛ller et al, 2002; McElwee et al, 2002).
The high numbers of CD4þ and CD8þ lymphocytes circum-
stantially suggest their involvement in hair follicle dystrophy.
CD4þ lymphocytes of the Th1 subset are responsible for
transfer of experimental autoimmune encephalomyelitis in
rodent models (McDonald and Swanborg, 1988; Karpus and
Swanborg, 1989; Mustafa et al, 1991). In experimental
autoimmune encephalomyelitis, activated pathogenic T cells
cross the blood^brain barrier and secrete proin£ammatory
cytokines and chemokines that attract other leukocytes to the
local environment. Similarly in mouse AA, the putative
immune privilege of the anagen-stage hair follicle is quickly
broached by skin-draining lymph node cells derived from AA-
a¡ected mice transferred to non-AA-a¡ected littermates (Carroll
et al, 2002). Investigations to de¢ne the relevant subsets of
immune cells capable of transferring AA are in progress.
However, preliminary studies in which CD4þ or CD8þ cells
were targeted in rodent models demonstrated that removal of
one or the other population from AA-a¡ected individuals is
associated with hair regrowth. With recovery of the cell
population, there is a reinitiation of hair loss (McElwee et al,
1996; McElwee et al, 1999c; Carroll et al, 2002). The SCID/human
xenograft model has also provided data supporting a
collaboration between CD4þ and CD8þ cells to promote AA
(Gilhar et al, 2002). These and other studies suggest that CD4þ
and CD8þ cell subsets are capable of perpetuating the AA lesion.
In mouse and rat models, there is a clear division in distribution
between the CD4þ and CD8þ cell populations. CD4þ cells are
almost exclusively perifollicular, whereas CD8þ cells readily
penetrate the hair follicle to take up intrafollicular residency.
As such, these cells are likely to be the population with the
greatest pathogenic potential, leaving CD4þ cells possibly
providing CD8þ cell support and directly acting on the follicles
through intermediaries, including hair growth^inhibiting
cytokines, secretory Fas, and granzymes (Carroll et al, 2002; Z˛ller
et al, 2002; Freyschmidt-Paul et al, 2003).
Immune system regulation Subsequent to immune system
activation, other mechanisms of regulation must fail for AA
to develop and be perpetuated. CD4þ/CD25þ cells have been
identi¢ed as one of probably several lymphocyte regulatory cell
subsets that can restrain pathogenic cell activity. They are
essential for maintaining homeostasis, they are able to sup-
press the induction of autoimmune disease and suppress CD4þ/
CD25 cells, and they inhibit the e¡ector function of
autoreactive CD8þ cells (Suri-Payer et al, 1998; Gao et al, 1999;
Annacker et al, 2001). Little is currently known about immune
regulatory mechanisms in human AA. Recent studies in the
skin graft^induced AA mouse model revealed that CD4þ/
CD25þ cell levels drop signi¢cantly on activation of AA and
prior to the onset of overt hair loss (Z˛ller et al, 2002). In con-
trast, sham-grafted mice are able to maintain CD4þ/CD25þ
cell numbers and quickly recover normal in£ammatory cell
numbers after injury. This apparent active depression of
regulatory cells in AA-challenged mice may be a key factor in
AA susceptibility. This and other regulatory methods may be
defective in AA development, and their investigation may yield
further insight into the mechanisms of the disease.
ANTIGEN AND PRESENTATION
MHC restriction For autoimmune disease to occur, a sustained
activation of autoreactive lymphocytes is required. The amount
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and localization of the antigen presented, along with the
background responsiveness and regulation of the immune sys-
tem and the availability of high-avidity autoreactive lympho-
cytes, are de¢ning parameters in successful disease induction
(Ludewig et al, 2001). For the most part, lymphocytes recognize
antigenic peptides only in association with self MHC molecules
and are initially activated exclusively in lymphoid organs (Karrer
et al, 1997). Retrieval, processing, and presentation of antigenic
peptides are conducted by professional antigen-presenting cells.
The number of these cells, the duration of presentation, and the
quality of presentation help determine whether autoimmunity
occurs. Antigen-presenting cells are equipped with MHC class II
for presentation of antigens to T helper, CD4þ cells (Inaba et al,
1998) and particular MHC alleles are known to be associated with
autoimmune disease susceptibility (Nepom and Erlich, 1991). The
structural nature of the MHC molecule can permit preferential
binding of speci¢c antigenic peptides and may consequently
increase the level of antigen presentation to the degree that
autoimmunity may develop (Wucherpfennig et al, 1995;
Wucherpfennig, 2001). Studies with humans have de¢ned several
HLA gene alleles in association with the AA phenotype (de
Andrade et al, 1999; Colombe et al, 1999). In a genome-wide
analysis of the C3H/HeJ mouse model, a susceptibility locus for
AAwas identi¢ed within the region of H2, the mouse equivalent
of the human HLA region (Sundberg et al, 2003). More recently,
dendritic cells have been characterized as expressing MHC class I
and have the capacity to present antigens derived from apoptotic
cells via MHC I direct to CD8þ cells (Albert et al, 1998; Larsson
et al, 2001; Fonteneau et al, 2002). Although attempts to associate
MHC class I gene alleles with the AA phenotype have so far met
with little success, CD8þ cells are fundamentally involved in the
development of AA in rodent models (McElwee et al, 1996;
Carroll et al, 2002). Thus, in addition to MHC class II, MHC I
restriction may be important, and the presentation of antigens in
association with MHC I on dendritic cells may play a role in the
onset of AA.
Costimulation For AA to develop, the immune system must
be receptive to activation. Assuming that AA is an autoimmune
disease, this requires the presence of antigen-presenting cells pro-
viding excitatory stimuli for lymphocytes within the individual.
For successful lymphocyte stimulation to occur, antigen-
presenting cells must express costimulatory molecules, primarily
B7.1, B7.2, ICAM-1, and LFA3. These bind ligands CD28,
CTLA4, LFA1, and CD2 on naive lymphocytes, and this, in
association with MHC- restricted antigen presentation, induces
full lymphocyte activation. Recent £ow cytometry analysis
revealed signi¢cant changes in expression of costimulatory
molecule expression in both skin-in¢ltrating lymphocytes and
skin-draining lymph node-derived cells (Z˛ller et al, 2002).
Other studies have shown that monoclonal antibodies against
the costimulatory antigens B7.1 and B7.2 can inhibit the onset of
AA in the skin graft-induced mouse model, demonstrating the
importance of antigen-presenting cells in AA induction (Carroll
et al, 2002). Use of the same monoclonal antibodies in mice that
already overtly express AA has little e¡ect, however, indicating
that chronic AA involves multiple redundant pathogenic
mechanisms. Removal of one part of the pathogenic system is
not enough to block the perpetuation of the disease. This may
have implications for future treatment development and suggests
that a multitarget therapeutic approach may be superior to
targeting a single aspect of the immune system’s activity.
TARGET TISSUE
Loss of immune privilege The hair follicle is regarded as an
immune-privileged site (Westgate et al, 1991; Paus et al, 1999). In
human and rodent model AA, disease onset is associated with
increased expression of MHC class I and class II in the lower,
transient portion of anagen-stage hair follicles (Messenger and
Bleehan, 1985; Br˛cker et al, 1987; Zhang and Oliver, 1994).
Previously, it was postulated that a loss of immune privilege
through an abnormal increase in hair follicle MHC expression
might be the inductive factor for AA (Paus et al, 1993). However,
no evidence of constitutive MHC expression has been de¢ned in
rodent models in the transient portions of anagen-stage hair
follicles prior to in£ammatory cell in¢ltration of AA-a¡ected
hair follicles. Sham-graft injury that induces a localized
expression of MHC class II in hair follicles does not activate AA
(Z˛ller et al, 2002; McElwee, personal observations), and AA can
be readily transferred from a¡ected mice to normal-haired
recipient mice by skin grafting or by lymph node^derived cell
transfer (McElwee et al, 1998b; Carroll et al, 2002). This suggests
that hair follicle MHC expression is a consequence of
in£ammation, rather than a cause, probably because of the high
levels of IFN-g and TNF-a known to be expressed by
in£ammatory cells (Z˛ller et al, 2002). The expression of MHC
molecules by hair follicle keratinocytes is nonetheless likely to
be very important for the in¢ltration and disruption of hair
follicles by autoreactive lymphocytes.
Hair follicle immunoprotection is likely transient due to the
nature of the hair follicle cycle. Research suggests that the onset
of catagen is associated with an in¢ltration of immune cells;
candidate antigen-presenting cells (Parakkal, 1969; Westgate et al,
1991; Paus, 1996; Eichmˇller et al, 1998). Regression of the hair
follicle in catagen involves high levels of apoptosis and
signi¢cant remodeling of the lower, transient portion of the hair
follicle (Weedon and Strutton, 1981; Lindner et al, 1997). It is thus
possible that the immune system is constantly exposed to low
levels of hair follicle^derived antigens as the follicles cycle
through catagen and given the ability of dendritic cells to
present apoptosis-derived antigens. Autoimmune disease is not
regarded as an all-or-nothing event. Rather, there are degrees of
autoreactivity and a threshold level above which overt
autoimmune disease is induced (Ludewig et al, 2001; McElwee
et al, 1999b). A re£ection of this may be the low level of hair
follicle^speci¢c antibodies found in some humans and rodents
in the absence of overt AA (Tobin et al, 1994a; Tobin et al, 1994b;
Tobin et al, 1997). If, however, catagen regression became
disordered and the immune cell in¢ltrate associated with
catagen inappropriately presented antigenic peptides in associa-
tion with expression of costimulatory molecules, antigen
presentation to the immune system might breach the threshold
for stimulation of autoreactive cells. In a genetically susceptible
individual, resident in a permissible environment, AA might
follow. In the C3H/HeJ mouse model, AA is rapidly induced in
a normal-haired mouse by transplantation of AA-a¡ected skin,
indicating that what hair follicle immune privilege there may be
is little defense against the aggression of an activated immune
system (McElwee et al, 1998b).
Hair follicle defects The involvement of hair follicle defects in
susceptibility to human AA has been postulated and may be
involved in rodent model AA (Bystryn and Tamesis, 1991;
Goldsmith, 1991). Several studies based on AA models indicate
that the primary hair loss^inducing component of AA is the
immune system rather than a potential functional hair follicle
defect with in£ammation developing as a secondary event
(McElwee et al, 1996; McElwee et al, 1998b; McElwee et al, 1999c;
Carroll et al, 2002). However, it is possible that antigens are
inappropriately expressed within the hair follicles of AA-a¡ected
individuals such that the immune system is challenged. The
target antigen may be expressed at a higher density than is
appropriate, or the antigen may be expressed transiently at a
point within the hair follicle cycle at which it should not
normally be expressed. Alternatively, the inciting antigen may
be genetically or environmentally modi¢ed such that it is more
stimulatory to the immune system. Studies indicate that
structural modi¢cation of peptides can enhance binding to
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MHC molecules or alter T cell receptor (TCR) recognition and
so increase the degree and nature of antigen presentation
(Wucherpfennig, 2001). Thus, hair follicle defects in themselves
may not promote the clinical AA phenotype, but it is possible
that they may increase the chance of peptide recognition by
autoreactive cells and maintain antigen presentation at a high
level once autoimmune disease begins.
Hair follicle disruption While high cytokine expression in
isolation is not known as a trigger factor for autoimmune
disease development, high expression around and within the
target tissue in conjunction with other stimuli can enhance
disease pathogenesis (von Herrath et al, 1995). The in£ammatory
in¢ltrate in rodent models expresses high levels of both Th1-
and Th2-type cytokines (Z˛ller et al, 2002), some of which may
act directly on the hair follicle. TNF-a binding to its receptor is
required to promote apoptosis in experimental autoimmune
encephalomyelitis and in£ammatory bowel disease (Piguet et al,
1998; Kassiotis and Kollias, 2001). Similarly, TNF-a activity in
AA may have a negative impact on the survival of hair follicle
keratinocytes in AA. While the Th2-type cytokine IL-10 is
commonly regarded as a potential regulator of autoimmunity,
recent studies identi¢ed its pathogenic potential in the NOD
mouse model for autoimmune diabetes (Balasa et al, 2000). One
study using the mouse model and histocompatible mice de¢cient
in IL-10 suggests that IL-10 may also contribute to AA
susceptibility (Freyschmidt-Paul et al, 2002). IFN-g may promote
keratinocyte expression of MHCmolecules that aid other in£am-
matory mechanisms. Other cytokines may negatively regulate
keratinocyte cell proliferation and encourage hair follicles to
truncate their growth cycle and enter a telogen resting state
(Randall, 2001). Overall, cytokines may be signi¢cant modu-
lators of hair follicle disruption.
Cytotoxicity may also be mediated through Fas/Fas Ligand
(FasL) interaction. Expressed on activated lymphocytes, the
binding of Fas expressed on target cells by FasL on activated
lymphocytes, or released in a secretory form, results in apoptosis
for the target cell. This mechanism of tissue destruction is not
MHC restricted and has the potential to damage innocent
bystander cells not directly targeted by the pathogenic
lymphocyte clones. Fas/FasL signaling is also believed to
promote antigen presentation. Thus, Fas has multiple roles
(Siegel et al, 2000). In the C3H/HeJ mouse model for AA, Fas
and FasL are signi¢cantly di¡erentially expressed in skin-
in¢ltrating lymphocytes, and Fas is highly expressed on
dystrophic hair follicle keratinocytes (McElwee et al, 2002;
Freyschmidt-Paul et al, 2003). Histocompatible mice de¢cient in
Fas or FasL are comparatively resistant to the induction of AA,
a result similar to that de¢ned for insulin-dependent diabetes
mellitus models (Itoh et al, 1997; Su et al, 2000). This
resistance was in part localized to the skin as Fas- and FasL-
de¢cient skin transplanted to AA-a¡ected mice resisted im-
mune activity and continued to grow hair (Freyschmidt-Paul
et al, 2003). The possibility of an autocrine and paracrine action
of Fas and FasL within and between hair follicle keratinocytes
may add to the action of the in£ammatory in¢ltrate and may
explain why FasL-de¢cient hair follicles were also relatively
resistant to AA.
Lymphocytes may also e¡ect tissue damage through direct
cell-speci¢c mechanisms. Perforin, produced by cytotoxic cells,
is a potent mediator of cell lysis (Russell and Ley, 2002). For
perforin-induced lysis of target cells to occur, the TCR of
an autoreactive cell must ligand with the relevant antigenic
peptide presented in conjunction with MHC on the target cell.
Whether perforin-mediated cell destruction occurs in AA is
unknown, but the presence of highly activated CD8þ cells
within dystrophic hair follicles and the high expression of
MHC molecules on hair follicle keratinocytes circumstantially
suggest that MHC-restricted, perforin-mediated tissue damage
can occur in AA. Other cytotoxic cell mechanisms may also be
involved. Granzymes, which may gain access to target cells via
perforin or induce apoptosis independent of perforin through
binding cell surface receptors (Motyka et al, 2000), have been
identi¢ed by microarray analysis as highly expressed in human
AA (Carroll et al, 2002). Inducible nitric oxide synthase
expression is apparent during mouse AA development and may
suggest a role for nitric oxide in disease pathogenesis (McElwee,
personal observation).
Resistance to pathogenic mechanisms Hair follicles may
have some methods of resistance against these e¡ector mecha-
nisms of tissue damage. They may avoid total destruction by
entering a telogen resting state, where antigen expression is
much more limited. There is some argument as to whether there
is a signi¢cantly increased frequency of telogen-stage hair follicles
associated with human AA. In rodent models, AA progression is
typically characterized by an initial increase in dystrophic anagen
follicles, but, as individuals reach the chronic stable phase of
AA, most follicles are in a telogen state (McElwee, personal
observation). The natural properties of hair follicles and their
regenerative ability may also provide resistance to the destructive
capacity of cytotoxic lymphocytes. As long as dermal papilla cells
survive and remain in close communication with keratinocytes,
hair follicles may be reformed if in£ammation is removed.
In this way, despite the aggressive nature of the peri- and
intrafollicular in£ammation and the severe disruption of the hair
Figure1. Mechanism of alopecia areata. Unknown events lead to the
uptake and processing of antigens by antigen-presenting cells (APC) that
migrate to regional lymph nodes. The inciting antigens are o¡ered to a
receptive immune system in association with appropriate costimulation
to activate autoreactive T helper (Th) and T cytotoxic (Tc) lymphocytes,
whereas T regulatory (Tr) cells are depleted. Further stimulus through cy-
tokines may recruit antibody-producing (B) lymphocytes. Activated cells
migrate to the skin utilizing adhesion molecules and surround anagen-
stage hair follicles. Loss of hair follicle immune privilege permits in£am-
matory cell in¢ltration, hair follicle disruption, and uptake of antigen deb-
ris by APC that may lead to epitope spreading with disease progression.
Hair follicles may avoid irreversible damage by entering prolonged telo-
gen, whereas immune surveillance ensures truncation of any future anagen
initiation events.
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follicle unit, the possibility of spontaneous or treatment-elicited
recovery from AA is possible.
CONCLUSIONS
In our current understanding of rodent models, the development
of AA fundamentally involves a general genetic susceptibility
with possible supplementation by a variety of minor disease se-
verity^modifying genes. However, the actual onset of the disease
along with its extent, persistence, and resistance to treatment in a
given individual rodent or human may be modulated by epige-
netic factors, including diet, gonadal hormones, pathogens, and
other environmental in£uences. Both genetic and environmental
factors will modulate AA at three levels. The responsiveness of
the immune system may be in£uenced through pathogen, aller-
gen, stress, and toxin load, with sensitivity to each de¢ned by
genetics. The speci¢c inciting antigens and how they are pre-
sented to the immune system may be de¢ned by environment-
derived cross-reactive antigens or by inappropriate antigen expo-
sure in the hair follicle cycle, while genes may dictate the thresh-
old level required for stimulating autoreactive cells through the
nature of the inciting or cross-reactive self antigens, MHC,
TCR, costimulatory molecules, and regulatory cells.Within the
skin, the failure of anagen-stage hair follicle immune privilege
may be modulated by local resident pathogens or by physical
trauma, and the subsequent adhesion molecule expression, cell
in¢ltration, cytokine milieu, and hair follicle disruption may
involve a complex gene interaction.
Onset of AA is dependent on a sequence of events (Fig 1)
involving the presence of autoreactive lymphocytes with high
a⁄nity and avidity for hair follicle antigenic epitopes; antigen
retrieval, processing, and carriage to lymphoid organs; appropri-
ate antigen presentation in association with costimulation; de¢-
ciency of lymphocyte regulation; breakdown of immune
privilege in hair follicles and perhaps other hair follicle-speci¢c
defects; and failure of the hair follicle unit to resist the onslaught
of focal in£ammation. The primary mechanism of hair follicle
disruption in rodent AA is e¡ected by CD8þ lymphocytes in a
manner dependent on Th1 CD4þ lymphocytes. Although a
Th1-mediated mechanism is fundamental to AA development,
Th2 cell activity is also involved, particularly in the chronic
stages of disease. Without knowing the source of the speci¢c
antigen epitopes that trigger AA onset, it is not possible to
conclusively de¢ne AA as fundamentally autoimmune in
nature. However, rodent model research has produced signi¢cant
evidence consistent with this hypothesis.
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